title: [Modern times: back to past, back to future].
authors.forename: Jesús
authors.initials: J
authors.lastname: Feliu
authors.forename: Amaya
authors.initials: A
authors.lastname: Zabalza
authors.forename: Ricardo
authors.initials: R
authors.lastname: García-Muñoz
authors.forename: Eduardo
authors.initials: E
authors.lastname: Olavarría
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage; D000069283:Rituximab; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids; D011719:Pyrazines; D000069283:Rituximab; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine